Product Code: MCP-1217
This report analyzes the worldwide markets for Growth Factors (Blood and Tissue) in US$ Million by the following Types: Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, & Interleukins), and Tissue Growth Factors. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 101 companies including many key and niche players such as -
Amgen, Inc.
Bayer HealthCare Pharmaceuticals, Inc.
Biocon Ltd.
Biogen, Inc.
BioMimetic Therapeutics LLC
Biopharm GmbH
Table of Contents
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
- Quantitative Techniques & Analytics
Product Definitions and Scope of Study
- Blood Growth Factors
- Erythropoietins
- Colony Stimulating Factors
- Interferons
- Interleukins
- Tissue Growth Factors
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
- Growth Factors: A Preface
- Burgeoning Global Population Offers Significant Growth Opportunities
- Table 1: Ten Largest Populated Countries Worldwide (2015): Total Population (in Millions) (includes corresponding Graph/Chart)
- Table 2: World Population by Geographic Region (2015-2050) (in Millions) (includes corresponding Graph/Chart)
- Aging Global Population: Need for New Effective Drugs
- Table 3: Global Population Statistics for the 65+ Age Group (Male & Female) for Major Countries/Regions: 2015 (includes corresponding Graph/Chart)
- Table 4: Global Aging Population (in Thousands) by Age Group: 2010, 2015, 2025 & 2050 (includes corresponding Graph/Chart)
- Table 5: Aging (65+) Demographics as a Percentage of Total Population for Major Countries: 2010, 2015 & 2020 (includes corresponding Graph/Chart)
- Table 6: Elderly Population (65+ Years) as a % of Total Population (2010, 2015 & 2025) (includes corresponding Graph/Chart)
- Table 7: Global Life Expectancy at Age 60 and 80 Years: 2010-2015; 2020-2025; and 2045-2050 (includes corresponding Graph/Chart)
- Table 8: Life Expectancy for Select Countries in Number of Years: 2015 (includes corresponding Graph/Chart)
- Increasing Healthcare Spending in Emerging Markets: Opportunities in Store
- Table 9: Healthcare Spending as % of GDP in Select OECD Countries (2016) (includes corresponding Graph/Chart)
- Global Spending on Medicines: A Review
- Table 10: Global Pharmaceutical Spending (2017): Percentage Share Breakdown by Region/Country (includes corresponding Graph/Chart)
- Biologics: Rapidly Gaining Ground
- List of Biosimilar Drugs Approved by the US FDA (2017)
- List of Biosimilar Drugs Approved by the EMA (2017)
- Erythropoietin (EPO) Market: An Insight
- Anemia in CKD and Cancer Patients: Opportunity for EPO Therapy
- CKD Prevalence
- Table 11: Global Dialysis Patient Population by Geographic Region/Country (2017 & 2024): Percentage Breakdown of Patient Population for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America, and Rest of World (includes corresponding Graph/Chart)
- Table 12: Global Population of Kidney Disease Patients Undergoing Treatment by Type of Modality (2017 & 2020): Percentage Breakdown of Patients Undergoing Dialysis Therapy and Kidney Transplantation (includes corresponding Graph/Chart)
- Expanding Pool of ESRD and CKD Patients Triggers Sustained Opportunities
- Table 13: Increasing Number of ESRD Patients Worldwide: 2015-2024 (includes corresponding Graph/Chart)
- Table 14: ESRD Prevalence in Select Countries (2014): Number of ESRD Patients Per Million Population in EU-28, Japan, Taiwan, USA and Global (includes corresponding Graph/Chart)
- Table 15: Worldwide Population of Potential Untreated ESRD Patients by Country (2016): Percentage Breakdown of Patient Population for Brazil, China, India, and Others (includes corresponding Graph/Chart)
- Rising Tide of Lifestyle Diseases - The Grim Reality Fueling Growth in Renal Diseases
- Global Diabetic Statistics - Opportunity Indicators
- Table 16: Worldwide Diabetes Prevalence (%) in Adults by Age Group and Gender (2015) (includes corresponding Graph/Chart)
- Table 17: World Diabetes and Population Statistics (2015 & 2040) (includes corresponding Graph/Chart)
- Table 18: Global Prevalence of Diabetes - Number of Adults Diagnosed with Diabetes (in Million) by Gender for 2015 & 2040 (includes corresponding Graph/Chart)
- Table 19: Number of Adults with Diagnosed Diabetes in Urban and Rural Areas (2015 & 2040) (In Million) (includes corresponding Graph/Chart)
- Table 20: Top 10 Countries with Highest Number of Adults Diagnosed with Diabetes (in Million) for 2015 & 2040 (includes corresponding Graph/Chart)
- Table 21: Global Diabetes Mellitus Incidence among Ages 20-79 (2014 & 2035P): Prevalence (in Millions) and Percentage Share by Geographic Region (includes corresponding Graph/Chart)
- Table 22: Percentage Increase in DM Incidence among Ages 20-79 Worldwide by Geographic Region: 2013-2035 (includes corresponding Graph/Chart)
- Table 23: Hypertension Prevalence (%) Worldwide by Region in Male and Females Aged 25+ Years (includes corresponding Graph/Chart)
- Table 24: Worldwide Prevalence of Hypertension (BP>=140 OR DBP>=90) (age-standardized estimate) among Male and Female (2014): Breakdown by Select Countries
- Competition in EPO Market
- Leading EPO Drugs Worldwide
- Comparison of Erythropoietin-Based Drugs in the US and European Union
- Safety & Efficacy Issues Concerning ESAs
- Serum Half-Life: A Key Attribute Differentiating ESAs
- Interferons Market: Rising Demand for Specialized Therapies to Drive Growth
- Patent Expiries of Major Interferon Drugs
- Colony Stimulating Factors (CSFs) Market in Myeloma Patients
- Neurotrophic Therapeutics: Recent Advancements & Challenges
- Clinical Trial Status of Neurotrophin Therapy for Major Neurodegenerative Diseases (2012)
- Interleukin-17 Market for Psoriasis Treatment: Positive Opportunities
- Anti-IL-6 Pathways for RA Treatment: Favorable Prospects
- Blood Growth Factors: Improving Circulation & Mobility in Peripheral Artery Disease Patients
- Wound Management Market and Cellular Growth Factors
- Growth Factors for Wound Management - A Snapshot
- Table 25: Global Wound Growth Factors Market (2017): Percentage Share Breakdown of Sales by Region (includes corresponding Graph/Chart)
- Multiple Sclerosis Drugs Market: Competition Set to Intensify
- Interferon-based Drugs for HCV Treatment: An Insight
- Patent Expiries Fuel Competition and Sales
- Patent Expiries of Biopharmaceuticals in Europe and United States
- Innovative Delivery System Shows Potential for Accelerating Use of Growth Factors
- Cytokines: Vital Growth Propellers for the Future of New Drugs
- Brain Derived Neurotrophic Factor (BDNF) Finds Increased Application
- Mimetic Growth Factors - Promising Potential
- New Technologies - Challenge to Growth Factors Market
- Influence of Neurotrophic Factors on Brain Cell Development
- Side Effects - Still a Concern
- Combination of Interferons and Ribavirin Develops More Anemia Cases
- Development of Cost Effective Methods - Need of the Hour
- hMSC-based Therapies to Drive Need for Growth Factors
2. GROWTH FACTORS - AN OVERVIEW
- Blood Growth Factors
- Erythropoietins
- Types of Erythropoietins
- Epoetin
- Darbepoetin
- Aranesp(r)
- Aranesp Vs. Other EPOs
- Recombinant Human EPO (rHuEPO)
- Colony Stimulating Factors
- Granulocyte-Colony Stimulating Factor
- Granulocyte Macrophage-Colony Stimulating Factor
- Other Colony Stimulating Factors
- Macrophage Colony Stimulating Factor (M-CSF)
- Key Functions of M-CSF
- Side-Effects of Colony-Stimulating Factors
- Interferons
- Types of Interferons
- Interferon-gamma
- 1a and 1b: Two Key Biochemical Forms of Interferon-B
- PEG-Intron
- Interleukins
- Tissue Growth Factors
- Wound Healing Growth Factors
- Neurotrophic Growth Factors
- Vascular Endothelial Growth Factor (VEGF)
- Fibroblast Growth Factor (FGF)
- Insulin-Like Growth Factor-I (IGF-I)
- Insulin-Like Growth Factor-II (IGF-II)
- Tissue Growth Factors: Classification Based on Key Source and Principal Activity
- Platelet-Derived Growth Factors in Wound Healing
- Growth Factors: Their Mode of Action in Tissue Repair
- Angiogenesis: Their Role in Wound Healing
- Angiogenesis as an Alternative for Cardiac Stents
- Applications of Growth Factors
- Growth Factors: Site/Course of Action and Applications
3. PRODUCT INNOVATIONS/ APPROVALS/INTRODUCTIONS
- Chugai Receives Japanese Approval for MIRCERA(r)
- Janssen Receives Breakthrough Therapy Designation from FDA for erdafitinib
- Bayer Receives Chinese FDA Approval for Eylea(r)
- FDA Approves Breakthrough Therapy Designation for Avelumab-INLYTA(r) Combination
- HumanZyme Introduces HumanKine(r) Interferon Gamma
- Genentech Receives FDA Approval for Actemra(r)
- FDA Approves Janssen Biotech's TREMFYA(tm)
- Novartis Launches Scapho(r) in India
4. RECENT INDUSTRY ACTIVITY
- Sanofi Acquires Bioverativ
- Adello Announces Acceptance of Application for Biosimilar Fligrastim by FDA
- Merck Divests Biosimilars Business
- Sangamo Changes Name to Sangamo Therapeutics
5. FOCUS ON SELECT PLAYERS
- Amgen, Inc. (USA)
- Bayer HealthCare Pharmaceuticals, Inc. (USA)
- Biocon Ltd. (India)
- Biogen, Inc. (USA)
- BioMimetic Therapeutics LLC (USA)
- Biopharm GmbH (Germany)
- Bolder BioTechnology, Inc. (USA)
- F. Hoffmann-La Roche AG (Switzerland)
- Chugai Pharmaceutical Co. Ltd. (Japan)
- Genentech, Inc. (USA)
- FibroGen, Inc. (USA)
- Johnson & Johnson (USA)
- Janssen Biotech, Inc. (USA)
- Lonza Group (Switzerland)
- Merck Serono (Germany)
- PeproTech, Inc. (USA)
- Reliance GeneMedix Plc (UK)
- Sangamo Therapeutics, Inc. (USA)
- Sanofi (France)
- Scil Proteins GmbH (Germany)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Wockhardt Ltd. (India)
6. GLOBAL MARKET PERSPECTIVE
- Table 26: World Recent Past, Current & Future Analysis for Growth Factors (Blood and Tissue) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
- Table 27: World Historic Review for Growth Factors (Blood and Tissue) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 28: World 14-Year Perspective for Growth Factors (Blood and Tissue) by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
- Table 29: World Recent Past, Current & Future Analysis for Blood Growth Factors by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
- Table 30: World Historic Review for Blood Growth Factors by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 31: World 14-Year Perspective for Blood Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
- Table 32: World Recent Past, Current & Future Analysis for Blood Growth Factors by Type - Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
- Table 33: World Historic Review for Blood Growth Factors by Type - Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 34: World 14-Year Perspective for Blood Growth Factors by Type - Percentage Breakdown of Value Sales for Erythropoietins, Colony Stimulating Factors, Interferons and Interleukins Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
- Table 35: World Recent Past, Current & Future Analysis for Erythropoietins by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
- Table 36: World Historic Review for Erythropoietins by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 37: World 14-Year Perspective for Erythropoietins by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
- Table 38: World Recent Past, Current & Future Analysis for Colony Stimulating Factors by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
- Table 39: World Historic Review for Colony Stimulating Factors by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 40: World 14-Year Perspective for Colony Stimulating Factors by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
- Table 41: World Recent Past, Current & Future Analysis for Interferons as Blood Growth Factors by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
- Table 42: World Historic Review for Interferons as Blood Growth Factors by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 43: World 14-Year Perspective for Interferons as Blood Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
- Table 44: World Recent Past, Current & Future Analysis for Interleukins as Blood Growth Factors by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
- Table 45: World Historic Review for Interleukins as Blood Growth Factors by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 46: World 14-Year Perspective for Interleukins as Blood Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
- Table 47: World Recent Past, Current & Future Analysis for Tissue Growth Factors by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
- Table 48: World Historic Review for Tissue Growth Factors by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 49: World 14-Year Perspective for Tissue Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
III. MARKET
1. THE UNITED STATES
- A. Market Analysis
- Current and Future Analysis
- Erythropoietin (EPO) Market: Amgen Continues to Dominate
- Leading EPO Drugs in the US
- Interferon Market: An Insight
- Colony Stimulating Factors (CSF) Market: An Overview
- Emerging Competitors in the G-CSF Market
- List of Biosimilar Drugs Approved by the US FDA (2017)
- US Fuels Long-term Biosimilars Market
- Table 50: Pharmaceutical Industry in the US (2017): Percentage Share Breakdown of Value Sales for Generic and Non-Generic Segments (includes corresponding Graph/Chart)
- CDER: A Regulatory Review Authority for Growth Factors
- Product Launches/Approvals/Innovations
- Strategic Corporate Developments
- Select Players
- B. Market Analytics
- Table 51: US Recent Past, Current & Future Analysis for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, and Interleukins), and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
- Table 52: US Historic Review for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, and Interleukins), and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 53: US 14-Year Perspective for Growth Factors by Type - Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, and Interleukins), and Tissue Growth Factors Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
2. CANADA
- Market Analysis
- Table 54: Canadian Recent Past, Current & Future Analysis for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, and Interleukins), and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
- Table 55: Canadian Historic Review for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, and Interleukins), and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 56: Canadian 14-Year Perspective for Growth Factors by Type - Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, and Interleukins), and Tissue Growth Factors Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
3. JAPAN
- A. Market Analysis
- Outlook
- Erythropoietin Market
- Leading EPO Drugs in Japan
- HCV Infection: Combination Therapy Dominates
- Product Approval
- Chugai Pharmaceutical Co. Ltd. - A Key Player
- B. Market Analytics
- Table 57: Japanese Recent Past, Current & Future Analysis for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, and Interleukins), and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
- Table 58: Japanese Historic Review for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, and Interleukins), and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 59: Japanese 14-Year Perspective for Growth Factors by Type - Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, and Interleukins), and Tissue Growth Factors Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
4. EUROPE
- A. Market Analysis
- Outlook
- Erythropoietin Market
- Leading Branded EPO Drugs in Europe
- Biosimilars Market
- Table 60: Biosimilar Penetration in Select EU Countries
- List of Biosimilar Drugs Approved by the EMA (2017)
- Strategic Corporate Development
- Select Players
- B. Market Analytics
- Table 61: European Recent Past, Current & Future Analysis for Growth Factors by Geographic Region - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
- Table 62: European Historic Review for Growth Factors by Geographic Region - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 63: European 14-Year Perspective for Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
- Table 64: European Recent Past, Current & Future Analysis for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, and Interleukins), and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
- Table 65: European Historic Review for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, and Interleukins), and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 66: European 14-Year Perspective for Growth Factors by Type - Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, and Interleukins), and Tissue Growth Factors Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
5. ASIA-PACIFIC
- Market Analysis
- Table 67: Asia-Pacific Recent Past, Current & Future Analysis for Growth Factors by Geographic Region - China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
- Table 68: Asia-Pacific Historic Review for Growth Factors by Geographic Region - China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 69: Asia-Pacific 14-Year Perspective for Growth Factors by Geographic Region - Percentage Breakdown of Value Sales for China and Rest of Asia-Pacific Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
- Table 70: Asia-Pacific Recent Past, Current & Future Analysis for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, and Interleukins), and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
- Table 71: Asia-Pacific Historic Review for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, and Interleukins), and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 72: Asia-Pacific 14-Year Perspective for Growth Factors by Type - Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, and Interleukins), and Tissue Growth Factors Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
5a. CHINA
- A. Market Analysis
- Outlook
- Erythropoietin Market
- Table 73: Leading Players in the Chinese EPO Market (2017): Percentage Share Breakdown of Value Sales for 3SBio, Beijing Sihuan, Harbin Pharma, Nanjin Huaxin Pharma, and Others (includes corresponding Graph/Chart)
- Injectable Interferons: The Only Treatment for HCV Patients
- Hepatitis B Market: Smaller Role of Interferons
- G-CSF Market: Competitive Landscape
- Table 74: G-CSF Market in China (2017): Percentage Share Breakdown of Revenues by Agent - Filgrastim, Lenograstim, Molgramostim, Nartograstim, and Others (includes corresponding Graph/Chart)
- Table 75: Leading Manufacturers in the Chinese G-CSF Market (2017): Percentage Share Breakdown of Revenues for Hangzhou Jiuyuan, Jiangsu Wuzhong Pharma, Qilu Pharma, Roche, Xiamen Amoytop Bio, Xiehe Fajio Qilin, and Others (includes corresponding Graph/Chart)
- Biologics Market: An Overview
- Key Statistical Findings
- Table 76: Interleukins Market in China (2017): Percentage Share Breakdown of Value Sales by Type - Interleukin-11 and Interleukin-2 (includes corresponding Graph/Chart)
- Table 77: Leading Players in the Chinese Interleukins Market (2017): Percentage Share Breakdown of Value Sales for E China Pharm, Four Rings, QG Pharm, Qilu Pharm, SL Pharm, and Others (includes corresponding Graph/Chart)
- Table 78: Interferon Market in China (2017): Percentage Share Breakdown of Value Sales by Type of Interferon (includes corresponding Graph/Chart)
- Table 79: Leading Players in the Chinese Interferons Market (2017): Percentage Share Breakdown of Value Sales for Hualida Bio, Huaxin Bio, Merck, Roche, Sinovac, Tri-Prime Gene, and Others (includes corresponding Graph/Chart)
- Product Approval
- B. Market Analytics
- Table 80: Chinese Recent Past, Current & Future Analysis for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, and Interleukins), and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
- Table 81: Chinese Historic Review for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, and Interleukins), and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 82: Chinese 14-Year Perspective for Growth Factors by Type - Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, and Interleukins), and Tissue Growth Factors Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
5b. REST OF ASIA-PACIFIC
- A. Market Analysis
- Current and Future Analysis
- India
- Biopharmaceutical Drugs Market: Promising Opportunities
- Select Biosimilars Developed in India
- Erythropoietins
- G-CSF Market
- Interferons
- Product Launch
- Select Players
- B. Market Analytics
- Table 83: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, and Interleukins), and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
- Table 84: Rest of Asia-Pacific Historic Review for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, and Interleukins), and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 85: Rest of Asia-Pacific 14-Year Perspective for Growth Factors by Type - Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, and Interleukins), and Tissue Growth Factors Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
6. REST OF WORLD
- A. Market Analysis
- Current and Future Analysis
- Brazil
- HCV Therapy Market: Interferons Widely in Use
- Teva Pharmaceutical Industries Ltd. (Israel) - A Key Global Player
- B. Market Analytics
- Table 86: Rest of World Recent Past, Current & Future Analysis for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, and Interleukins), and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
- Table 87: Rest of World Historic Review for Growth Factors by Type - Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, and Interleukins), and Tissue Growth Factors Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
- Table 88: Rest of World 14-Year Perspective for Growth Factors by Type - Percentage Breakdown of Value Sales for Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, and Interleukins), and Tissue Growth Factors Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)
